Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Capital Leases (2024 - 2026)

Denali Therapeutics has reported Capital Leases over the past 2 years, most recently at $5.5 million for Q4 2025.

  • Quarterly Capital Leases fell 1.48% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, down 1.48% year-over-year, with the annual reading at $5.5 million for FY2025, 1.48% down from the prior year.
  • Capital Leases was $5.5 million for Q4 2025 at Denali Therapeutics, roughly flat from $5.6 million in the prior quarter.
  • Over five years, Capital Leases peaked at $5.6 million in Q3 2024 and troughed at $5.5 million in Q4 2025.